Get the Stockscreener App
0.1065
0.47%
0.0005
After Hours:
.11
0.0035
+3.29%
Applied Therapeutics Inc stock is traded at $0.1065, with a volume of 7.12M.
It is up +0.47% in the last 24 hours and down -50.83% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.106
Open:
$0.1069
24h Volume:
7.12M
Relative Volume:
0.57
Market Cap:
$15.37M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.0789
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
+6.50%
1M Performance:
-50.83%
6M Performance:
-68.27%
1Y Performance:
-86.72%
1-Day Range:
$0.103
$0.114
1-Week Range:
$0.0976
$0.114
52-Week Range:
$0.0911
$1.50
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.1065 | 15.30M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Can Applied Therapeutics Inc. stock beat analyst upgradesAnalyst Downgrades & Low Risk Capital Appreciation - ulpravda.ru
RSI Check: Why Applied Therapeutics Inc stock attracts global investorsJuly 2025 Technicals & Growth-Oriented Investment Plans - moha.gov.vn
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options - MSN
EBITDA per share of Applied Therapeutics, Inc. – FWB:2UV - TradingView — Track All Markets
Applied Therapeutics $15M Securities Class Action Settlement - Claim Depot
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - MSN
Applied Therapeutics (APLT) price target decreased by 85.00% to 0.26 - MSN
Will Applied Therapeutics Inc. stock see insider buyingQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - bolumsonucanavari.com
Why Applied Therapeutics Inc. stock remains a top recommendationMarket Sentiment Summary & Fast Moving Trade Plans - bolumsonucanavari.com
What analyst consensus says on Applied Therapeutics Inc. stockStop Loss & Risk Managed Investment Strategies - Улправда
Is Applied Therapeutics Inc. (2UV) stock cheap vs fundamentalsWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Applied Therapeutics Inc. stock maintain momentum in 2025 - Bölüm Sonu Canavarı
Is Applied Therapeutics Inc. stock a safe buy before earningsQuarterly Market Review & Fast Gaining Stock Strategy Reports - Улправда
How Applied Therapeutics Inc. (2UV) stock stacks up against competitorsMarket Performance Report & Safe Swing Trade Setup Alerts - DonanımHaber
Why Applied Therapeutics Inc. stock is recommended by analysts2025 Fundamental Recap & Long-Term Investment Growth Plans - Улправда
Applied Therapeutics, Inc.(NasdaqCM: APLT) dropped from NASDAQ Biotechnology Index - marketscreener.com
Published on: 2025-12-19 02:08:41 - Улправда
Dir Kanter Sells 43,000 ($4.8K) Of Applied Therapeutics Inc [APLT] - TradingView — Track All Markets
Applied Therapeutics (APLT) director reports sale of 43,000 shares on Form 4 - Stock Titan
Published on: 2025-12-18 17:03:31 - Улправда
Applied Therapeutics Earnings Notes - Trefis
United StatesGoodwin Represents Cycle Pharmaceuticals In Acquisition Of Applied Therapeutics - Mondaq
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now - Finviz
Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Dir Kanter Files To Sell 43,000 Of Applied Therapeutics Inc [APLT] - TradingView — Track All Markets
British drugs company Cycle Pharma snaps up US competitor - The Times
Applied Therapeutics announces merger with Cycle Group - MSN
Halper Sadeh LLC Encourages ALEX, DXLG, APLT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Applied Therapeutics to be acquired by Cycle Pharmaceuticals - MSN
RBC Capital Sticks to Its Hold Rating for Applied Therapeutics (APLT) - The Globe and Mail
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-ALEX, DVS, DXLG, and APLT - The Malaysian Reserve
Applied Therapeutics stock rating downgraded to Neutral by Baird - Investing.com Canada
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
S&P 500 Down 1%; Broadcom Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cycle Pharma to acquire Applied Therapeutics - The Pharma Letter
Cycle Group Holdings Limited entered into a definitive agreement to acquire Applied Therapeutics, Inc. for $13.4 million. - marketscreener.com
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - Benzinga
Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - ts2.tech
RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk - marketscreener.com
APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Applied Therapeutics Announces Merger with Cycle Group - TipRanks
Applied Therapeutics plunges after UK's Cycle Group to buy co - TradingView — Track All Markets
Applied Therapeutics stock price target lowered by RBC on Cycle acquisition - Investing.com Canada
Why Lululemon Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Applied Therapeutics To Be Acquired By Privately Held Cycle Group - Nasdaq
Cycle Pharmaceuticals to Acquire Applied Therapeutics - citybiz
Cycle Pharmaceuticals acquiring Applied Therapeutics - MSN
Cycle Group to Acquire Applied Therapeutics (APLT) in Strategic Deal - GuruFocus
Published on: 2025-12-05 04:31:49 - Newser
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):